Former Sandoz Inc. CEO Don DeGolyer Leads PharmaTech Startup Ategenos as Company Prepares Public Launch
CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- Ategenos, a pharmatech company, today announced that Co-Founder and Chief Executive Officer Don DeGolyer is leading the company as it prepares to exit stealth and unveil its platform addressing one of healthcare's most costly and persistent challenges: medication non-adherence.
Logo of Ategenos, a PharmaTech company focused on connected drug delivery
Ategenos has been quietly developing a novel platform that integrates pharmaceutical science with real-time digital health technologies to address adherence in critical dose management. The company will share details on its SmartPatch platform and initial partnerships in the coming weeks.
"Medication doesn't work if it's not taken. Yet non-adherence remains one of the biggest drivers of avoidable healthcare costs worldwide," said DeGolyer. "From the start, we set out to build a platform that combines drug delivery, actionable real-world data, and caregiver intervention. We provide caregivers the peace of mind that their loved ones have taken their critical dose medicines and are not at risk of a catastrophic health event."
Medication non-adherence contributes to an estimated 125,000 preventable deaths and more than $500 billion in avoidable healthcare costs annually in the U.S., with global costs exceeding $1 trillion each year.
DeGolyer brings over 40 years of leadership across the pharmaceutical industry. As President & CEO of Sandoz Inc., he grew revenues by $2 billion in four years, building one of the largest generics businesses in North America. As COO of Endo Pharmaceuticals, he helped scale the company from $2 billion to $18 billion in market cap within two years. He also founded and led Vertice Pharmaceuticals, doubling revenue during his tenure and building a platform that later contributed to a $700 million strategic sale. Don has held senior roles at Pfizer, Johnson & Johnson, and Novartis, advisory positions with Koch Investment Group and Formation Bio, and serves on the board of Emergent BioSolutions.
DeGolyer has built a founding team combining pharma leadership, MIT-rooted technology innovation, and venture capital expertise. With experience spanning drug delivery, IoT, real-world data, and company building, Ategenos is uniquely positioned to operate at the intersection of pharmaceuticals and technology.
About Ategenos
Ategenos is a Massachusetts-based PharmaTech company improving quality of life for patients and their families with its SmartPatch platform—an advanced transdermal system that combines sustained drug delivery with real-time monitoring and caregiver interventions. The technology reduces health risks, hospitalizations, and the $1T+ global costs caused by missed doses of critical medications. The company's founders uniquely combine global pharma leadership, MIT-driven technology, and a proven track record of building and scaling healthcare platforms.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
The Democratic Party's Brand Is Cooked
Voters have increasingly little faith in the Democrats, a new Wall Street Journal poll found, with the party reaching its lowest favorability rating in more than three decades. Voters overwhelmingly believe that Republicans are better able to handle key issues in Congress than Democrats. The survey found that the majority of voters, 63 percent, have an unfavorable view of the Democratic Party. Only 33 percent hold a favorable view. This is the most unpopular that Democrats have been according to Journal polls dating back to 1990. As President Donald Trump enacts an increasingly authoritarian agenda and provides little economic benefit to the average American, Democrats are hopeful anti-Trump backlash will give them a strong showing in the 2026 midterm election. While slightly more people expect to vote for Democrats next year than Republicans, according to the Journal poll, Democrats' overall favorability has only dropped since Trump took office. 'The Democratic brand is so bad that they don't have the credibility to be a critic of Trump or the Republican Party,' John Anzalone, a Democratic pollster who worked on the survey, told the Journal. 'Until they reconnect with real voters and working people on who they're for and what their economic message is, they're going to have problems.' Anzalone's firm, which consulted for both President Joe Biden and Vice President Kamala Harris' presidential campaigns, worked on the survey with Trump pollster Tony Fabrizio. According to the survey, voters think Republicans in Congress are more capable at handling the economy, inflation and rising prices, tariffs, immigration, 'illegal' immigration, the Russia-Ukraine war, and foreign policy. On the topic of 'illegal' immigration, 48 percent have their faith in Republicans and 24 percent choose Democrats. Democrats scored higher on health care and vaccine policy. Both parties tied at 37 percent on the issue of looking out for middle class families. 'As much as I fully believe that Democrats are not doomed for all eternity, I also believe that many Democrats aren't quite grappling with the serious credibility problems the party still faces,' Democratic operative Tré Easton posted on X. 'The podcasts and everything are real cute, but we've got work to do.' Democrats also scored low in a Quinnipiac poll released earlier this month. In that survey, approval of congressional Democrats reached a new low of 19 percent, with 72 percent of voters saying they disapproved. 'This is a record low since March 2009 when the Quinnipiac University Poll first began asking this question of registered voters,' the university wrote. The Quinnippiac poll found that even registered Democrats disapproved of the party: Thirty-nine percent approved of how Democrats in Congress were handling their jobs, while 52 percent disapproved. Among registered Republicans, 77 percent approved of how Republicans are operating in Congress. In the findings from the Journal, voters are mixed on Trump. About half, or 55 percent, of voters say the country is headed in the wrong direction. This is down from 70 percent in January, meaning voters have become more optimistic since Trump took office, yet Trump is not wildly popular. He has a favorability rating of 45 percent, and an unfavorability rating of 52 percent. A total of 46 percent approve of what Trump is doing as president, and 52 percent disapprove. Fifty-three percent disapprove of Trump's handling of the economy, while 44 percent approve. On the issues of inflation, tariffs, immigration, looking out for middle class families, health care, vaccine policy, foreign policy, and the Russia-Ukraine war, voters disapprove of the job Trump is doing. On the topic of 'illegal' immigration, though, 51 percent approve and 49 percent disapprove. The Republican Party is not wildly popular either, though, with 54 percent of voters having an unfavorable view, compared to the 43 percent who have a favorable view. More from Rolling Stone Trump Claims Someone May Have Forged His Signature on Birthday Letter to Epstein I Worked With Stephen Colbert. Here's Why His Cancellation Should Scare You Yes, America Is an Oligarchy Best of Rolling Stone The Useful Idiots New Guide to the Most Stoned Moments of the 2020 Presidential Campaign Anatomy of a Fake News Scandal The Radical Crusade of Mike Pence
Yahoo
4 minutes ago
- Yahoo
Blues Have Big Move To Make With Breakout Forward
The St. Louis Blues' decision to tender an offer sheet to forward Dylan Holloway this past off-season undoubtedly proved to be a great decision. After the Edmonton Oilers elected not to match the Blues' two-year, $4,580,914 offer sheet for Holloway, he broke out in a major way in his first season with St. Louis.
CBS News
6 minutes ago
- CBS News
Weiss Memorial Hospital's access to Medicare payments revoked, IDPH announced
The future of Weiss Memorial Hospital in Uptown is uncertain after the federal Department of Health and Human Services announced that it is revoking the facility's ability to receive Medicare payments. Starting on Aug. 9, Medicare won't pay Weiss for inpatient services. The move could be devastating for the safety-net hospital, which the Sun-Times reported received over half of its 2023 revenue from the program. While the notice didn't elaborate on why it deemed Weiss not "compliant" with its guidelines, the hospital's air-conditioning system failed last month, forcing dozens of patients to be transferred to its sister institution, West Suburban Hospital in Oak Park. Since then, Weiss has rendered only limited services to patients while it awaits spare parts to fix the air conditioning. In a statement, a spokesperson for the Illinois Department of Public Health said: "The Illinois Department of Public Health has been closely monitoring the situation at Weiss Memorial Hospital. As required by law, the results of our surveys of the hospital are shared with the federal Center for Medicare and Medicaid Services (CMS). CMS holds the authority to and made the decision to terminate Weiss's involvement with the Medicare program effective August 9, 2025. There is a process for reconsideration that Weiss can pursue. IDPH is committed to ensuring patient safety and quality of care at healthcare facilities in Illinois and will engage with Weiss as appropriate."
